Semin Musculoskelet Radiol 2023; 27(04): 463-470
DOI: 10.1055/s-0043-1770353
Review Article

Bone and Chronic Kidney Disease

Marie-Hélène Lafage-Proust 
1   INSERM U1059 SAINBIOSE Université Jean Monnet, Saint-Etienne, France
2   Service de Rhumatologie, CHU Saint-Etienne, Saint-Etienne, France
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Chronic kidney disease (CKD) induces mineral and bone disorders (CKD-MBD) that affect calcium and phosphate metabolism. This review links pathophysiology, histologic aspects, and radiologic signs. CKD leads to bone lesions, namely renal osteodystrophy, which may combine low or high bone remodeling, impaired mineralization, and bone loss. CKD-MBD also comprises vascular calcifications, which, together with bone disease, lead to a high risk of cardiovascular events and osteoporotic fractures that increase both morbidity and mortality. Osteoporosis assessment is based on screening for classic risk factors and CKD-related factors (disease duration/severity, transplantation history, dialysis vintage). Treatment of mineral disorders may combine serum phosphate lowering drugs, natural vitamin D or its 1-α derivatives, or calcium-sensing receptor agonists. Treatment of osteoporosis is conventional in mild to moderate stages but more complex in severe CKD because evidence about the efficacy and safety of anti-osteoporosis drugs is scant.

Keywords

osteoporosis - chronic kidney disease - renal osteodystrophy - fracture


Publication History

Article published online:
25 September 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Loos-Ayav C, Briançon S, Frimat L, André JL, Kessler M. pour le comité de pilotage EPIRAN. Incidence of chronic kidney disease in the general population, EPIRAN study [in French]. Nephrol Ther 2009; 5 (Suppl. 04) S250-S255
    PubMedGoogle Scholar
  • 2 Bongard V, Dallongeville J, Arveiler D. et al. Assessment and characteristics of chronic renal insufficiency in France [in French]. Ann Cardiol Angeiol (Paris) 2012; 61 (04) 239-244
    PubMedGoogle Scholar
  • 3 Jager KJ, Kovesdy C, Langham R, Rosenberg M, Jha V, Zoccali C. A single number for advocacy and communication—worldwide more than 850 million individuals have kidney diseases. Kidney Int 2019; 96 (05) 1048-1050
    CrossrefPubMedGoogle Scholar
  • 4 The CKD-EPI equation. Accessed June 5, 2023 at: http://www.soc-nephrologie.org/eservice/calcul/eDFG.htm
    PubMed
  • 5 Belkacem I, Galland B, Merle V. et al. Prévalence de l'IRCT et part des différentes modalités de traitement. Nephrol Ther 2022; x: 18
    PubMedGoogle Scholar
  • 6 Moe S, Drüeke T, Cunningham J. et al; Kidney Disease: Improving Global Outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006; 69 (11) 1945-1953
    CrossrefPubMedGoogle Scholar
  • 7 Salam SN, Eastell R, Khwaja A. Fragility fractures and osteoporosis in CKD: pathophysiology and diagnostic methods. Am J Kidney Dis 2014; 63 (06) 1049-1059
    CrossrefPubMedGoogle Scholar
  • 8 Novel-Catin E, Pelletier S, Fouque D. et al. Quantitative histomorphometric analysis of halved iliac crest bone biopsies yield comparable ROD diagnosis as full 7.5mm wide samples. Bone 2020; 138: 115460
    CrossrefPubMedGoogle Scholar
  • 9 Lavigne F, Desbiens LC, Garneau G, Côté F, Mac-Way F. Iliac crest bone biopsy by interventional radiologists to improve access to bone biopsy in chronic kidney disease populations: technical note and a case series. J Nephrol 2021; 34 (03) 901-906
    CrossrefPubMedGoogle Scholar
  • 10 Sprague SM, Bellorin-Font E, Jorgetti V. et al. Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis 2016; 67 (04) 559-566
    CrossrefPubMedGoogle Scholar
  • 11 Jørgensen HS, Behets G, Viaene L. et al. Diagnostic accuracy of noninvasive bone turnover markers in renal osteodystrophy. Am J Kidney Dis 2022; 79 (05) 667-676.e1
    CrossrefPubMedGoogle Scholar
  • 12 Jadoul M, Albert JM, Akiba T. et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006; 70 (07) 1358-1366
    CrossrefPubMedGoogle Scholar
  • 13 Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol 2006; 17 (11) 3223-3232
    CrossrefPubMedGoogle Scholar
  • 14 Klawansky S, Komaroff E, Cavanaugh Jr PF. et al. Relationship between age, renal function and bone mineral density in the US population. Osteoporos Int 2003; 14 (07) 570-576
    CrossrefPubMedGoogle Scholar
  • 15 Perez-Villa F, Lafage-Proust MH, Gielen E, Ortiz A, Spasovski G, Argilés À. The renal patient seen by non-renal physicians: the kidney embedded in the ‘milieu intérieur’. Clin Kidney J 2020; 14 (04) 1077-1087
    CrossrefPubMedGoogle Scholar
  • 16 Jannot M, Mac-Way F, Lapierre V, Lafage-Proust MH. The use of bone mineral density measured by dual energy X-ray absorptiometry (DXA) and peripheral quantitative computed microtomography in chronic kidney disease. J Nephrol 2017; 30 (05) 635-643
    CrossrefPubMedGoogle Scholar
  • 17 Yenchek RH, Ix JH, Shlipak MG. et al; Health, Aging, and Body Composition Study. Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol 2012; 7 (07) 1130-1136
    CrossrefPubMedGoogle Scholar
  • 18 Naylor KL, Garg AX, Zou G. et al. Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol 2015; 10 (04) 646-653
    CrossrefPubMedGoogle Scholar
  • 19 Iimori S, Mori Y, Akita W. et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients—a single-center cohort study. Nephrol Dial Transplant 2012; 27 (01) 345-351
    CrossrefPubMedGoogle Scholar
  • 20 Rampersad C, Whitlock RH, Leslie WD. et al. Trabecular bone score in patients with chronic kidney disease. Osteoporos Int 2020; 31 (10) 1905-1912
    CrossrefPubMedGoogle Scholar
  • 21 FRAX: Tool to Evaluate Fracture Risk [in French]. Accessed June 5, 2023 at: https://frax.shef.ac.uk/FRAX/tool.aspx?country=9
    PubMed
  • 22 Desbiens LC, Sidibé A, Beaudoin C, Jean S, Mac-Way F. Comparison of fracture prediction tools in individuals without and with early chronic kidney disease: a population-based analysis of CARTaGENE. J Bone Miner Res 2020; 35 (06) 1048-1057
    CrossrefPubMedGoogle Scholar
  • 23 Whitlock RH, Leslie WD, Shaw J. et al. The Fracture Risk Assessment Tool (FRAX®) predicts fracture risk in patients with chronic kidney disease. Kidney Int 2019; 95 (02) 447-454
    CrossrefPubMedGoogle Scholar
  • 24 Sigrist MK, Taal MW, Bungay P, McIntyre CW. Progressive vascular calcification over 2 years is associated with arterial stiffening and increased mortality in patients with stages 4 and 5 chronic kidney disease. Clin J Am Soc Nephrol 2007; 2 (06) 1241-1248
    CrossrefPubMedGoogle Scholar
  • 25 Evenepoel P, Cunningham J, Ferrari S. et al; European Renal Osteodystrophy (EUROD) workgroup, an initiative of the CKD-MBD working group of the ERA-EDTA, and the committee of Scientific Advisors and National Societies of the IOF. European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4-G5D. Nephrol Dial Transplant 2021; 36 (01) 42-59
    CrossrefPubMedGoogle Scholar
  • 26 Evenepoel P, D'Haese P, Bacchetta J. et al; ERA-EDTA Working Group on CKD-MBD. Bone biopsy practice patterns across Europe: the European renal osteodystrophy initiative—a position paper. Nephrol Dial Transplant 2017; 32 (10) 1608-1613
    PubMedGoogle Scholar
  • 27 Chen CH, Lo WC, Hu PJ. et al. Efficacy of osteoporosis medications for patients with chronic kidney disease: an updated systematic review and network meta-analysis. Front Pharmacol 2022; 13: 822178
    CrossrefPubMedGoogle Scholar
  • 28 Miller PD, Roux C, Boonen S, Barton IP, Dunlap LE, Burgio DE. Safety and efficacy of risedronate in patients with age-related reduced renal function as estimated by the Cockcroft and Gault method: a pooled analysis of nine clinical trials. J Bone Miner Res 2005; 20 (12) 2105-2115
    CrossrefPubMedGoogle Scholar
  • 29 Miller PD, Schwartz EN, Chen P, Misurski DA, Krege JH. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporos Int 2007; 18 (01) 59-68
    CrossrefPubMedGoogle Scholar
  • 30 Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE. MORE Investigators. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol 2008; 19 (07) 1430-1438
    CrossrefPubMedGoogle Scholar
  • 31 Broadwell A, Chines A, Ebeling PR. et al. Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease. J Clin Endocrinol Metab 2021; 106 (02) 397-409
    CrossrefPubMedGoogle Scholar
  • 32 Miyauchi A, Hamaya E, Nishi K, Tolman C, Shimauchi J. Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease. J Bone Miner Metab 2022; 40 (04) 677-687
    CrossrefPubMedGoogle Scholar
  • 33 Chen H, Yang H, Jia P, Bao L, Tang H. Effectiveness of kyphoplasty in the treatment of osteoporotic vertebral compression fracture patients with chronic kidney disease. J Orthop Sci 2016; 21 (05) 571-578
    CrossrefPubMedGoogle Scholar
  • 34 Iseri K, Carrero JJ, Evans M. et al. Secular trends in hip fracture incidence and subsequent mortality in dialysis patients and the general population in Sweden. Bone 2021; 147: 115909
    CrossrefPubMedGoogle Scholar